Related Experiment Video
Updated: Jun 26, 2026
06:38
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Temsirolimus in renal cell carcinoma
1Städtische Kliniken Lukaskrankenhaus, Neuss, Germany. thomas_otto@lukasneuss.de
Transplantation Proceedings
|December 23, 2008
Summary
Temsirolimus significantly improved overall survival for patients with advanced renal cell carcinoma (RCC). This targeted therapy was well-tolerated and offers new treatment strategies for this poor-prognosis cancer.
Area of Science:
- Oncology
- Pharmacology
Background:
- Metastatic renal cell carcinoma (RCC) presents a poor prognosis with limited treatment efficacy.
- Targeted therapies offer potential for improved outcomes in advanced RCC.
Purpose of the Study:
- To describe the single-center treatment experiences with temsirolimus in patients with advanced RCC under a compassionate use program.
- To evaluate the tolerability and clinical benefit of temsirolimus in this patient population.
Main Methods:
- Retrospective analysis of 200 patients with advanced RCC treated with temsirolimus via a compassionate use program.
- Evaluation of treatment tolerability and side effect profiles.
Main Results:
- Temsirolimus demonstrated a significant increase in median overall survival for poor-risk, advanced RCC patients (10.9 months) compared to historical controls.
- The treatment was generally well-tolerated, with manageable side effects including mucositis, diabetes, and peripheral edema.
- This study represents the first Phase III trial demonstrating overall survival improvement with a targeted therapy in advanced RCC.
Conclusions:
- Temsirolimus provides a clinically beneficial treatment option for advanced RCC, particularly in poor-risk patients.
- Further investigations into temsirolimus in combination with bevacizumab and as second-line therapy are warranted.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...